Apparent seizure and atrial fibrillation associated with paliperidone

American Journal of Health-System Pharmacy

Volumn 65, Issue 22, 2008, Pages 2122-2125

  Schneider, Rebekah A ^a   Lizer, Mitsi H ^b  

^a Winchester Medical Center   (United States)

^b SHENANDOAH UNIVERSITY   (United States)

Author keywords

Antipsychotic agents; Anxiolytics, sedatives and hypnotics; Atrial fibrillation; Clonazepam; Diazepam; Dosage; Electrolytes; Enalapril; Escitalopram; Insulin glargine; Insulin lispro; Lamotrigine; Metformin; Paliperidone; Potassium chloride; Seizures; Simvastatin

Indexed keywords

ACETYLSALICYLIC ACID; CLONAZEPAM; DILTIAZEM; ENALAPRIL; ESCITALOPRAM; HEPARIN; INSULIN GLARGINE; INSULIN LISPRO; LAMOTRIGINE; METFORMIN; PALIPERIDONE; POTASSIUM CHLORIDE; SIMVASTATIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; PRIORITY JOURNAL; QT PROLONGATION; SEIZURE; SINGLE DRUG DOSE; ST SEGMENT; SYMPTOM; T WAVE;

EID: 56749156801     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070615     Document Type: Article

References (11)

1. Invega (paliperidone) package insert. Mountainville, CA: Ortho-McNeil-Janssen Pharmaceuticals; 2007.
2. Kane J, Canas F, Kramer M et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007; 90:147-61.
3. Kramer M, Simpson G, Maciulis V et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007; 27:6-14. [Erratum, J Clin Psychopharmacol. 2007; 27:258.]
4. Davidson M, Emsley R, Kramer M et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007; 93:117-30. [Erratum, Schizophr Res. 2007; 96:273-4.]
5. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
6. Pisani F, Oteri G, Costa C et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002; 25:91-110.
7. Collaborative Working Group on Clinical Trial Evaluations. Adverse effects of the atypical antipsychotics. J Clin Psychiatry. 1998; 59(suppl 12):17-22.
8. Risperdal (risperidone) package insert. Mountainville, CA: Ortho-McNeil-Janssen Pharmaceuticals; 2005.
9. Alldredge BK. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology. 1999; 53(5, suppl 2):S68-75.
10. Acri AA, Henretig FM. Effects of risperidone in overdose. Am J Emerg Med. 1998; 16:498-501.
11. Adverse Event Reporting System standard report: risperidone and paliperidone case reports of seizures, United States, 1997-2007. Rockville, MD: Center for Drug Evaluation and Research; 2007:1-452.